Maintenance therapy in acute myeloid leukemia revisited: Will new agents rekindle an old interest?

Current Opinion in Hematology

Volumn 17, Issue 2, 2010, Pages 85-90

  Krug, Utz ^a   Lübbert, Michael ^b   Büchner, Thomas ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Acute myeloid leukemia; Maintenance therapy; New targeted drugs

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALPHA INTERFERON; AZACITIDINE; BEVACIZUMAB; CILENGITIDE; CYTARABINE; DASATINIB; FLT3 LIGAND; IMATINIB; INTERLEUKIN 2; LENALIDOMIDE; MIDOSTAURIN; MITOXANTRONE; NORETHANDROLONE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RETINOIC ACID; SEMAXANIB; SORAFENIB; STANOZOLOL; STEM CELL FACTOR; TIPIFARNIB; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ACUTE GRANULOCYTIC LEUKEMIA; BONE MARROW TOXICITY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG CHOICE; HUMAN; MAINTENANCE THERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW;

AZACITIDINE; BENZENESULFONATES; ENZYME INHIBITORS; HUMANS; LEUKEMIA, MYELOID, ACUTE; PRENYLATION; PROTEIN-TYROSINE KINASES; PYRIDINES; STAUROSPORINE;

EID: 76749119418     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3283366bf4     Document Type: Review

References (40)

1. Rai KR, Holland JF, Glidewell OJ, et al. Treatment of acute myelocytic leukemia: a study by Cancer and Leukemia Group B. Blood 1981; 58: 1203-1212.
2. Buchner T, Urbanitz D, Hiddemann W, et al. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol 1985; 3:1583-1589.
3. Buchner T, Hiddemann W, Wormann B, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood 1999; 93:4116-4124.
4. Buchner T, Hiddemann W, Berdel WE, et al. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol 2003; 21:4496-4504.
5. Buchner T, Berdel WE, Schoch C, et al. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol 2006; 24:2480-2489.
6. Buchner T, Berdel WE, Haferlach C, et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 2009; 27:61-69.
7. Glover AB, Leyland-Jones BR, Chun HG, et al. Azacitidine: 10 years later. Cancer Treat Rep 1987; 71:737-746.
8. Schmelz K, Sattler N, Wagner M, et al. Induction of gene expression by 5-aza-2'-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and-independent mechanisms. Leukemia 2005; 19:103-111.
9. Kuendgen A, Lubbert M. Current status of epigenetic treatment in myelodysplastic syndromes. Ann Hematol 2008; 87:601-611.
10. Flotho C, Claus R, Batz C, et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 2009; 23:1019-1028.
11. Agrawal S, Unterberg M, Koschmieder S, et al. DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia. Cancer Res 2007; 67:1370-1377.
12. Zittoun R, Jehn U, Fiere D, et al. Alternating v repeated postremission treatment in adult acute myelogenous leukemia: a randomized phase III study (AML6) of the EORTC Leukemia Cooperative Group. Blood 1989; 73:896-906.
13. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 2002; 20:2429-2440.
14. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10:223-232.
15. Grovdal M, Khan R, Aggerholm A, et al. Maintenance treatment with azacytidine for patients with high risk myelodysplastic syndromes or acute myeloid leukaemia in complete remission after intensive chemotherapy. Blood 2007; 110:251a.
16. Wijermans PW, Krulder JW, Huijgens PC, Neve P. Continuous infusion of low-dose 5-aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 1997; 11:1-5. (Pubitemid 27065040)
17. Wijermans PW, Lübbert M, Verhoef G, et al. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients. Ann Hematol 2005; 84 (Suppl 1):9-17.
18. Rüter B, Wijermans PW, Lübbert M. Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2'-deoxycytidine retreatment in high-risk myelodysplasia patients. Cancer 2006; 106:1744-1750.
19. Lü bbert M, Schmid M, Ruter B, et al. Continued treatment with an outpatient maintenance schedule of decitabine in older AML patients ineligible for induction chemotherapy: results of the 00331 phase II multicenter trial. Blood 2008; 112:1018-1019a.
20. Haas PS, Wijermans P, Verhoef G, Lübbert M. Treatment of myelodysplastic syndrome with a DNA methyltransferase inhibitor: lack of evidence for induction of chromosomal instability. Leuk Res 2006; 30:338-342.
21. Yang AS, Estecio MR, Garcia-Manero G, et al. Comment on 'Chromosomal instability and tumors promoted by DNA hypomethylation' and 'Induction of tumors in nice by genomic hypomethylation'. Science 2003; 302:1153; author reply 1153.
22. Mesters RM, Padro T, Bieker R, et al. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood 2001; 98:241-243.
23. Sun L, Liang C, Shirazian S, et al. Discovery of 5-[5-fluoro-2-oxo-1,2- dihy-droindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 2003; 46:1116-1119. (Pubitemid 36428215)
24. Weisberg E, Boulton C, Kelly LM, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 2002; 1:433-443.
25. Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005; 105:54-60. (Pubitemid 40053063)
26. Krug U, Serve H, Müller-Tidow C, et al. New molecular therapy targets in acute myeloid leukemia. Recent Results Cancer Res 2007; 176:243-262.
27. Karp JE, Smith BD, Gojo I, et al. Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. Clin Cancer Res 2008; 14:3077-3082.
28. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000; 95:309-313.
29. Padro T, Ruiz S, Bieker R, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000; 95:2637-2644.
30. Fiedler W, Graeven U, Ergun S, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 1997; 89:1870-1875.
31. Meloni G, Trisolini SM, Capria S, et al. How long can we give interleukin-2? Clinical and immunological evaluation of AML patients after 10 or more years of IL2 administration. Leukemia 2002; 16:2016-2018.
32. Meloni G, Vignetti M, Pogliani E, et al. Interleukin-2 therapy in relapsed acute myelogenous leukemia. Cancer J Sci Am 1997; 3 (Suppl 1):S43-47.
33. Pautas C, Thomas X, Merabet F, et al. Randomized comparison of standard induction with daunorubicin (DNR) for 3 days vs idarubicin (IDA) for 3 or 4 days in AML pts aged 50 to 70 and of maintenance with interleukin 2. Final analysis of the ALFA 9801 study. Blood 2007; 110:55a.
34. Baer MR, George SL, Caligiuri MA, et al. Low-dose interleukin-2 immunother-apy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. J Clin Oncol 2008; 26:4934-4939.
35. Brune M, Castaigne S, Catalano J, et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and inter-leukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood 2006; 108:88-96.
36. Goldstone AH, Burnett AK, Wheatley K, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98:1302-1311.
37. Byron JW. Comparison of the action of 3 H-thymidine and hydroxyurea on testosterone-treated hemopoietic stem cells. Blood 1972; 40:198-203.
38. Hollard D, Sotto JJ, Berthier R, et al. High rate of long-term survivals in AML treated by chemotherapy and androgenotherapy: a pilot study. Cancer 1980; 45:1540-1548.
39. Hayat M, Jehn U, Willemze R, et al. A randomized comparison of maintenance treatment with androgens, immunotherapy, and chemotherapy in adult acute myelogenous leukemia. A Leukemia-Lymphoma Group Trial of the EORTC. Cancer 1986; 58:617-623.
40. Pigneux P, Himberlin C, Hunault-Berger M, et al. Improved outcome with androgens as maintenance treatment in elderly patients with acute myeloid leukemia after ICL regimen as induction therapy: results of the GOELAMS SA-2002 multicenter phase III randomized open trial. Haematologica 2009; 94:337-338a.